$IOVA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in IOVANCE BIOTHERAPEUTICS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in IOVANCE BIOTHERAPEUTICS, INC.. Get notifications about new insider transactions in IOVANCE BIOTHERAPEUTICS, INC. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 16 2021 | IOVA | IOVANCE BIOTHERAPE ... | BILINSKY IGOR | Chief Operating Off ... | Option Exercise | A | 34.91 | 150,000 | 5,236,500 | 150,000 | |
| Jan 06 2021 | IOVA | IOVANCE BIOTHERAPE ... | Swartzburg Michael | Vice President, Fin ... | Option Exercise | A | 46.26 | 45,000 | 2,081,700 | 45,000 | |
| Dec 17 2020 | IOVA | IOVANCE BIOTHERAPE ... | Bellemin Jean-Marc | Chief Financial Off ... | Option Exercise | A | 50.26 | 150,000 | 7,539,000 | 150,000 | |
| Jun 10 2020 | IOVA | IOVANCE BIOTHERAPE ... | Dukes Iain D. | Director | Option Exercise | A | 32.17 | 70,000 | 2,251,900 | 70,000 | |
| Jun 10 2020 | IOVA | IOVANCE BIOTHERAPE ... | MCPEAK MERRILL A | Director | Option Exercise | A | 32.17 | 35,000 | 1,125,950 | 35,000 | |
| Jun 10 2020 | IOVA | IOVANCE BIOTHERAPE ... | WEISER MICHAEL | Director | Option Exercise | A | 32.17 | 35,000 | 1,125,950 | 35,000 | |
| Jun 10 2020 | IOVA | IOVANCE BIOTHERAPE ... | Maynard Ryan D | Director | Option Exercise | A | 32.17 | 35,000 | 1,125,950 | 35,000 | |
| Jun 10 2020 | IOVA | IOVANCE BIOTHERAPE ... | Countouriotis Athena | Director | Option Exercise | A | 32.17 | 35,000 | 1,125,950 | 35,000 | |
| Jun 02 2020 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 33.12 | 1,894 | 62,729 | 298,786 | 300.7 K to 298.8 K (-0.63 %) |
| May 04 2020 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 32.00 | 1,894 | 60,608 | 300,680 | 302.6 K to 300.7 K (-0.63 %) |
| Feb 05 2020 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 22.54 | 1,302 | 29,347 | 305,389 | 306.7 K to 305.4 K (-0.42 %) |
| Jan 07 2020 | IOVA | IOVANCE BIOTHERAPE ... | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Offic ... | Option Exercise | A | 25.54 | 75,000 | 1,915,500 | 75,000 | |
| Jan 07 2020 | IOVA | IOVANCE BIOTHERAPE ... | Vogt Frederick G | General Counsel | Option Exercise | A | 25.54 | 150,000 | 3,831,000 | 150,000 | |
| Jan 07 2020 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Option Exercise | A | 25.54 | 500,000 | 12,770,000 | 500,000 | |
| Jan 07 2020 | IOVA | IOVANCE BIOTHERAPE ... | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Offic ... | Option Exercise | A | 25.54 | 75,000 | 1,915,500 | 75,000 | |
| Jan 07 2020 | IOVA | IOVANCE BIOTHERAPE ... | Vogt Frederick G | General Counsel | Option Exercise | A | 25.54 | 150,000 | 3,831,000 | 150,000 | |
| Jan 07 2020 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Option Exercise | A | 25.54 | 500,000 | 12,770,000 | 500,000 | |
| Jan 06 2020 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 26.68 | 1,562 | 41,674 | 306,691 | 308.3 K to 306.7 K (-0.51 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 22.66 | 1,894 | 42,918 | 308,253 | 310.1 K to 308.3 K (-0.61 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 21.97 | 1,894 | 41,611 | 310,147 | 312 K to 310.1 K (-0.61 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 18.21 | 1,894 | 34,490 | 312,041 | 313.9 K to 312 K (-0.60 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 20.27 | 1,610 | 32,635 | 313,935 | 315.5 K to 313.9 K (-0.51 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 25.17 | 1,321 | 33,250 | 315,545 | 316.9 K to 315.5 K (-0.42 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 24.62 | 1,321 | 32,523 | 316,866 | 318.2 K to 316.9 K (-0.42 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 18.04 | 1,321 | 23,831 | 318,187 | 319.5 K to 318.2 K (-0.41 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 11.14 | 1,321 | 14,716 | 319,508 | 320.8 K to 319.5 K (-0.41 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 9.78 | 1,321 | 12,919 | 320,829 | 322.2 K to 320.8 K (-0.41 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 10.77 | 1,298 | 13,979 | 322,150 | 323.4 K to 322.2 K (-0.40 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 9.26 | 1,562 | 14,464 | 323,448 | 325 K to 323.4 K (-0.48 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 9.45 | 1,562 | 14,761 | 325,010 | 326.6 K to 325 K (-0.48 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 10.44 | 1,321 | 13,791 | 326,572 | 327.9 K to 326.6 K (-0.40 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 9.62 | 1,321 | 12,708 | 327,893 | 329.2 K to 327.9 K (-0.40 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 11.12 | 1,321 | 14,690 | 329,214 | 330.5 K to 329.2 K (-0.40 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 17.10 | 1,321 | 22,589 | 330,535 | 331.9 K to 330.5 K (-0.40 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 13.70 | 1,321 | 18,098 | 331,856 | 333.2 K to 331.9 K (-0.40 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 12.80 | 1,321 | 16,909 | 333,177 | 334.5 K to 333.2 K (-0.39 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 14.55 | 1,321 | 19,221 | 334,498 | 335.8 K to 334.5 K (-0.39 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 14.60 | 1,321 | 19,287 | 335,819 | 337.1 K to 335.8 K (-0.39 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 16.90 | 1,321 | 22,325 | 337,140 | 338.5 K to 337.1 K (-0.39 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 18.15 | 1,321 | 23,976 | 338,461 | 339.8 K to 338.5 K (-0.39 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 16.50 | 1,525 | 25,163 | 339,782 | 341.3 K to 339.8 K (-0.45 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 8.00 | 1,562 | 12,496 | 341,307 | 342.9 K to 341.3 K (-0.46 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 8.80 | 1,994 | 17,547 | 342,869 | 344.9 K to 342.9 K (-0.58 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 7.15 | 1,994 | 14,257 | 344,863 | 346.9 K to 344.9 K (-0.57 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 7.75 | 1,993 | 15,446 | 346,857 | 348.9 K to 346.9 K (-0.57 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 6.00 | 1,994 | 11,964 | 348,850 | 350.8 K to 348.9 K (-0.57 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 5.70 | 1,993 | 11,360 | 350,844 | 352.8 K to 350.8 K (-0.56 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 7.35 | 1,994 | 14,656 | 352,837 | 354.8 K to 352.8 K (-0.56 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 5.45 | 143,496 | 782,053 | 354,831 | 498.3 K to 354.8 K (-28.80 %) |
| Dec 04 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Payment of Exercise | F | 7.15 | 51,673 | 369,462 | 498,327 | 550 K to 498.3 K (-9.40 %) |
| Jul 19 2019 | IOVA | IOVANCE BIOTHERAPE ... | GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Offic ... | Option Exercise | A | 25.78 | 160,000 | 4,124,800 | 160,000 | |
| Jun 11 2019 | IOVA | IOVANCE BIOTHERAPE ... | MCPEAK MERRILL A | Director | Option Exercise | A | 19.93 | 35,000 | 697,550 | 35,000 | |
| Jun 11 2019 | IOVA | IOVANCE BIOTHERAPE ... | Dukes Iain D. | Director | Option Exercise | A | 19.93 | 70,000 | 1,395,100 | 70,000 | |
| Jun 11 2019 | IOVA | IOVANCE BIOTHERAPE ... | Maynard Ryan D | Director | Option Exercise | A | 19.93 | 35,000 | 697,550 | 35,000 | |
| Jun 11 2019 | IOVA | IOVANCE BIOTHERAPE ... | WEISER MICHAEL | Director | Option Exercise | A | 19.93 | 50,000 | 996,500 | 50,000 | |
| Jun 11 2019 | IOVA | IOVANCE BIOTHERAPE ... | Countouriotis Athena | Director | Option Exercise | A | 19.93 | 35,000 | 697,550 | 35,000 | |
| Mar 06 2019 | IOVA | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Option Exercise | A | 11.26 | 400,000 | 4,504,000 | 400,000 | |
| Mar 06 2019 | IOVA | IOVANCE BIOTHERAPE ... | Vogt Frederick G | General Counsel | Option Exercise | A | 11.26 | 200,000 | 2,252,000 | 200,000 | |
| Mar 06 2019 | IOVA | IOVANCE BIOTHERAPE ... | MORRIS TIMOTHY E | Chief Financial Off ... | Option Exercise | A | 11.26 | 100,000 | 1,126,000 | 100,000 | |
| Dec 20 2018 | IOVA | IOVANCE BIOTHERAPE ... | Dukes Iain D. | Director | Buy | P | 8.65 | 12,000 | 103,796 | 12,000 | 0 to 12 K |
| Dec 14 2018 | IOVA | IOVANCE BIOTHERAPE ... | MCPEAK MERRILL A | Director | Buy | P | 9.63 | 10,000 | 96,273 | 456,583 | 446.6 K to 456.6 K (+2.24 %) |
| Dec 07 2018 | IOVA | IOVANCE BIOTHERAPE ... | Rothbaum Wayne P. | Director | Buy | P | 9.86 | 300,000 | 2,958,000 | 7,067,333 | 6.8 M to 7.1 M (+4.43 %) |
| Dec 07 2018 | IOVA | IOVANCE BIOTHERAPE ... | Rothbaum Wayne P. | Director | Buy | P | 10.31 | 921,053 | 9,496,056 | 6,767,333 | 5.8 M to 6.8 M (+15.75 %) |
| Jul 19 2018 | IOVA | IOVANCE BIOTHERAPE ... | WEISER MICHAEL | Director | Option Exercise | A | 14.45 | 35,000 | 505,750 | 35,000 | |
| Jul 19 2018 | IOVA | IOVANCE BIOTHERAPE ... | MCPEAK MERRILL A | Director | Option Exercise | A | 14.45 | 35,000 | 505,750 | 35,000 | |
| Jul 19 2018 | IOVA | IOVANCE BIOTHERAPE ... | Dukes Iain D. | Director | Option Exercise | A | 14.45 | 70,000 | 1,011,500 | 70,000 | |
| Jul 19 2018 | IOVA | IOVANCE BIOTHERAPE ... | Maynard Ryan D | Director | Option Exercise | A | 14.45 | 35,000 | 505,750 | 35,000 | |
| Mar 19 2018 | IOVA | IOVANCE BIOTHERAPE ... | WEISER MICHAEL | Director | Option Exercise | A | 16.20 | 50,000 | 810,000 | 50,000 | |
| Feb 12 2018 | LBIO | IOVANCE BIOTHERAPE ... | Fardis Maria | President and CEO | Option Exercise | A | 16.80 | 500,000 | 8,400,000 | 500,000 | |
| Jan 08 2018 | LBIO | IOVANCE BIOTHERAPE ... | Vogt Frederick G | General Counsel | Option Exercise | A | 8.00 | 37,400 | 299,200 | 37,400 | |
| Sep 12 2017 | LBIO | IOVANCE BIOTHERAPE ... | Dukes Iain D. | Director | Option Exercise | A | 7.30 | 150,000 | 1,095,000 | 150,000 | |
| Aug 16 2017 | LBIO | IOVANCE BIOTHERAPE ... | MORRIS TIMOTHY E | Chief Financial Off ... | Option Exercise | A | 5.05 | 250,000 | 1,262,500 | 250,000 | |
| Jun 05 2017 | LBIO | Lion Biotechnologi ... | Dukes Iain D. | Director | Option Exercise | A | 5.45 | 70,000 | 381,500 | 70,000 | |
| Jun 05 2017 | LBIO | Lion Biotechnologi ... | MCPEAK MERRILL A | Director | Option Exercise | A | 5.45 | 35,000 | 190,750 | 35,000 | |
| Jun 05 2017 | LBIO | Lion Biotechnologi ... | Maynard Ryan D | Director | Option Exercise | A | 5.45 | 35,000 | 190,750 | 35,000 | |
| Jun 05 2017 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Option Exercise | A | 5.45 | 35,000 | 190,750 | 35,000 | |
| Jun 05 2017 | LBIO | Lion Biotechnologi ... | Venkatesan Jay | Director | Option Exercise | A | 5.45 | 35,000 | 190,750 | 35,000 | |
| Nov 15 2016 | LBIO | Lion Biotechnologi ... | SCHIFFMAN GREGORY T | Chief Financial Off ... | Option Exercise | A | 7.55 | 300,000 | 2,265,000 | 300,000 | |
| Aug 24 2016 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Sell | S | 9.11 | 54,000 | 491,740 | 100,000 | 154 K to 100 K (-35.06 %) |
| Aug 18 2016 | LBIO | Lion Biotechnologi ... | Dukes Iain D. | Director | Option Exercise | A | 9.10 | 35,000 | 318,500 | 35,000 | |
| Aug 18 2016 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Option Exercise | A | 9.10 | 35,000 | 318,500 | 35,000 | |
| Aug 18 2016 | LBIO | Lion Biotechnologi ... | Venkatesan Jay | Director | Option Exercise | A | 9.10 | 35,000 | 318,500 | 35,000 | |
| Aug 18 2016 | LBIO | Lion Biotechnologi ... | Maynard Ryan D | Director | Option Exercise | A | 9.10 | 35,000 | 318,500 | 35,000 | |
| Aug 18 2016 | LBIO | Lion Biotechnologi ... | MCPEAK MERRILL A | Director | Option Exercise | A | 9.10 | 35,000 | 318,500 | 35,000 | |
| Aug 18 2016 | LBIO | Lion Biotechnologi ... | Maynard Ryan D | Director | Option Exercise | A | 9.10 | 35,000 | 318,500 | 35,000 | |
| Aug 18 2016 | LBIO | Lion Biotechnologi ... | MCPEAK MERRILL A | Director | Option Exercise | A | 9.10 | 35,000 | 318,500 | 35,000 | |
| Aug 18 2016 | LBIO | Lion Biotechnologi ... | Fardis Maria | President and CEO | Option Exercise | A | 9.10 | 35,000 | 318,500 | 35,000 | |
| Jun 15 2016 | LBIO | Lion Biotechnologi ... | Henderson Molly | CFO | Option Exercise | A | 7.61 | 50,000 | 380,500 | 50,000 | |
| Jun 15 2016 | LBIO | Lion Biotechnologi ... | Henderson Molly | CFO | Option Exercise | A | 5.87 | 150,000 | 880,500 | 150,000 | |
| Jun 09 2016 | LBIO | Lion Biotechnologi ... | Fardis Maria | President & CEO | Option Exercise | A | 5.87 | 500,000 | 2,935,000 | 500,000 | |
| Jun 09 2016 | LBIO | Lion Biotechnologi ... | Fardis Maria | President & CEO | Grant | A | 0.00 | 550,000 | 0 | 550,000 | 0 to 550 K |
| Mar 30 2016 | LBIO | Lion Biotechnologi ... | Lotze Michael | Chief Scientific Of ... | Option Exercise | A | 4.54 | 225,000 | 1,021,500 | 225,000 | |
| Mar 16 2016 | LBIO | Lion Biotechnologi ... | HAWKINS ELMA | President & CEO | Option Exercise | A | 5.05 | 275,000 | 1,388,750 | 275,000 | |
| Mar 15 2016 | LBIO | Lion Biotechnologi ... | Henderson Molly | Chief Financial Off ... | Option Exercise | A | 5.05 | 100,000 | 505,000 | 100,000 | |
| Mar 15 2016 | LBIO | Lion Biotechnologi ... | Bender James G. | Vice President - Ma ... | Option Exercise | A | 5.05 | 30,000 | 151,500 | 30,000 | |
| Apr 21 2016 | LBIO | Lion Biotechnologi ... | Fischkoff Steven A. | Chief Medical Offic ... | Option Exercise | A | 5.43 | 225,000 | 1,221,750 | 225,000 | |
| Dec 30 2015 | LBIO | Lion Biotechnologi ... | HAWKINS ELMA | President and CEO | Option Exercise | A | 7.58 | 58,939 | 446,758 | 58,939 | |
| Dec 30 2015 | LBIO | Lion Biotechnologi ... | HAWKINS ELMA | President and CEO | Option Exercise | M | 0.00 | 40,000 | 0 | 160,000 | |
| Dec 30 2015 | LBIO | Lion Biotechnologi ... | HAWKINS ELMA | President and CEO | Payment of Exercise | F | 8.98 | 23,988 | 215,412 | 176,567 | 200.6 K to 176.6 K (-11.96 %) |
| Dec 30 2015 | LBIO | Lion Biotechnologi ... | HAWKINS ELMA | President and CEO | Buy | M | 0.00 | 40,000 | 0 | 200,555 | 160.6 K to 200.6 K (+24.91 %) |
| Dec 30 2015 | LBIO | Lion Biotechnologi ... | Henderson Molly | Chief Financial Off ... | Option Exercise | A | 7.58 | 21,116 | 160,059 | 21,116 | |
| Dec 30 2015 | LBIO | Lion Biotechnologi ... | Bender James G. | Vice President, Man ... | Option Exercise | A | 7.58 | 27,622 | 209,375 | 27,622 | |
| Dec 30 2015 | LBIO | Lion Biotechnologi ... | Bender James G. | Vice President, Man ... | Payment of Exercise | F | 5.76 | 11,274 | 64,938 | 88,726 | 100 K to 88.7 K (-11.27 %) |
| Sep 09 2015 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Sell | S | 7.13 | 16,500 | 117,645 | 154,000 | 170.5 K to 154 K (-9.68 %) |
| Sep 09 2015 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Sell | S | 6.84 | 16,000 | 109,440 | 170,500 | 186.5 K to 170.5 K (-8.58 %) |
| Aug 04 2015 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Sell | S | 8.15 | 32,500 | 264,875 | 186,500 | 219 K to 186.5 K (-14.84 %) |
| Jun 16 2015 | LBIO | Lion Biotechnologi ... | Maynard Ryan D | Director | Option Exercise | A | 11.05 | 35,000 | 386,750 | 35,000 | |
| Jun 16 2015 | LBIO | Lion Biotechnologi ... | Venkatesan Jay | Director | Option Exercise | A | 11.05 | 35,000 | 386,750 | 35,000 | |
| Jun 15 2015 | LBIO | Lion Biotechnologi ... | MCPEAK MERRILL A | Director | Option Exercise | A | 11.05 | 35,000 | 386,750 | 35,000 | |
| Jun 15 2015 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Option Exercise | A | 11.05 | 35,000 | 386,750 | 35,000 | |
| Jun 10 2015 | LBIO | Lion Biotechnologi ... | Henderson Molly | Chief Financial Off ... | Option Exercise | A | 10.69 | 200,000 | 2,138,000 | 200,000 | |
| May 08 2015 | LBIO | Lion Biotechnologi ... | Ayer Capital Management, LP | 10% Owner | Sell | S | 9.62 | 2,780,682 | 26,752,385 | 2,823,333 | 5.6 M to 2.8 M (-49.62 %) |
| May 07 2015 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Sell | S | 10.00 | 50,000 | 500,000 | 219,000 | 269 K to 219 K (-18.59 %) |
| Feb 17 2015 | LBIO | Lion Biotechnologi ... | Maynard Ryan D | Director | Option Exercise | A | 7.45 | 50,000 | 372,500 | 50,000 | |
| Jan 29 2015 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Option Exercise | J | 2.50 | 25,000 | 62,500 | 0 | |
| Jan 29 2015 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Option Exercise | A | 2.50 | 25,000 | 62,500 | 25,000 | |
| Jan 29 2015 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Sell | J | 0.00 | 25,000 | 0 | 0 | 25 K to 0 (-100.00 %) |
| Jan 29 2015 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
| Dec 09 2014 | LBIO | Lion Biotechnologi ... | Radvanyi Laszlo | Chief Scientific Of ... | Option Exercise | A | 6.25 | 32,407 | 202,544 | 32,407 | |
| Dec 09 2014 | LBIO | Lion Biotechnologi ... | Venkatesan Jay | Director | Option Exercise | A | 6.25 | 50,000 | 312,500 | 50,000 | |
| Dec 09 2014 | LBIO | Lion Biotechnologi ... | MCPEAK MERRILL A | Director | Option Exercise | A | 6.25 | 50,000 | 312,500 | 50,000 | |
| Dec 09 2014 | LBIO | Lion Biotechnologi ... | Handelman Michael D | Chief Financial Off ... | Option Exercise | A | 6.25 | 40,000 | 250,000 | 40,000 | |
| Dec 09 2014 | LBIO | Lion Biotechnologi ... | Bender James G. | Vice President, Man ... | Option Exercise | A | 6.25 | 46,666 | 291,663 | 46,666 | |
| Dec 09 2014 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Option Exercise | A | 6.25 | 50,000 | 312,500 | 50,000 | |
| Nov 07 2014 | LBIO | Lion Biotechnologi ... | BRISTOL INVESTMENT FUND LTD | 10% Owner | Sell | S | 690,000.00 | 100,000 | 69,000,000,000 | 3,867,863 | 4 M to 3.9 M (-2.52 %) |
| Oct 07 2014 | LBIO | Lion Biotechnologi ... | Radvanyi Laszlo | Chief Scientific Of ... | Option Exercise | A | 5.80 | 180,000 | 1,044,000 | 180,000 | |
| Oct 07 2014 | LBIO | Lion Biotechnologi ... | Radvanyi Laszlo | Chief Scientific Of ... | Grant | A | 0.00 | 180,000 | 0 | 180,000 | 0 to 180 K |
| Sep 17 2014 | LBIO | Lion Biotechnologi ... | HAWKINS ELMA | President & COO | Option Exercise | A | 6.70 | 125,000 | 837,500 | 125,000 | |
| Jul 23 2014 | LBIO | Lion Biotechnologi ... | Ayer Capital Management, LP | Director | Option Exercise | C | 1.25 | 1 | 1 | 0 | |
| Jul 23 2014 | LBIO | Lion Biotechnologi ... | Ayer Capital Management, LP | Director | Option Exercise | C | 1.25 | 1 | 1 | 0 | |
| Jul 23 2014 | LBIO | Lion Biotechnologi ... | Ayer Capital Management, LP | Director | Option Exercise | C | 1.00 | 1 | 1 | 0 | |
| Jul 23 2014 | LBIO | Lion Biotechnologi ... | Ayer Capital Management, LP | Director | Option Exercise | C | 1.00 | 1 | 1 | 0 | |
| Jul 23 2014 | LBIO | Lion Biotechnologi ... | Ayer Capital Management, LP | Director | Buy | J | 0.05 | 560,088,650 | 27,444,344 | 560,401,150 | 312.5 K to 560.4 M (+179,228.37 %) |
| May 16 2014 | LBIO | Lion Biotechnologi ... | Handelman Michael D | Chief Financial Off ... | Option Exercise | A | 0.00 | 75,000 | 0 | 75,000 | |
| May 16 2014 | LBIO | Lion Biotechnologi ... | Handelman Michael D | Chief Financial Off ... | Option Exercise | A | 7.95 | 75,000 | 596,250 | 75,000 | |
| Mar 05 2014 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Option Exercise | A | 5.65 | 40,000 | 226,000 | 40,000 | |
| Mar 05 2014 | LBIO | Lion Biotechnologi ... | Venkatesan Jay | Director | Option Exercise | A | 5.65 | 40,000 | 226,000 | 40,000 | |
| Mar 05 2014 | LBIO | Lion Biotechnologi ... | MCPEAK MERRILL A/ | Director | Option Exercise | A | 5.65 | 40,000 | 226,000 | 40,000 | |
| Jan 22 2014 | LBIO | Lion Biotechnologi ... | Singh Manish | President and CEO | Grant | A | 0.00 | 607,500 | 0 | 2,546,000 | 1.9 M to 2.5 M (+31.34 %) |
| Jan 16 2014 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Grant | A | 0.00 | 67,500 | 0 | 269,000 | 201.5 K to 269 K (+33.50 %) |
| Jan 13 2014 | LBIO | Lion Biotechnologi ... | Bender James G. | Vice President, Man ... | Option Exercise | A | 9.60 | 100,000 | 960,000 | 100,000 | |
| Jan 13 2014 | LBIO | Lion Biotechnologi ... | Bender James G. | Vice President, Man ... | Grant | A | 0.00 | 100,000 | 0 | 100,000 | 0 to 100 K |
| Nov 12 2013 | LBIO | Lion Biotechnologi ... | MCPEAK MERRILL A/ | Director | Option Exercise | A | 2.50 | 50,000 | 125,000 | 50,000 | |
| Nov 12 2013 | LBIO | Lion Biotechnologi ... | MCPEAK MERRILL A/ | Director | Buy | P | 2.00 | 50,000 | 100,000 | 396,432 | 346.4 K to 396.4 K (+14.43 %) |
| Nov 07 2013 | LBIO | Lion Biotechnologi ... | Singh Manish | President & CEO | Option Exercise | A | 2.50 | 125,000 | 312,500 | 125,000 | |
| Nov 07 2013 | LBIO | Lion Biotechnologi ... | Singh Manish | President & CEO | Buy | P | 2.00 | 125,000 | 250,000 | 1,938,500 | 1.8 M to 1.9 M (+6.89 %) |
| Nov 07 2013 | LBIO | Lion Biotechnologi ... | Singh Manish | President & CEO | Grant | A | 0.00 | 607,500 | 0 | 1,813,500 | 1.2 M to 1.8 M (+50.37 %) |
| Nov 07 2013 | LBIO | Lion Biotechnologi ... | Hillsberg Sanford | Director | Grant | A | 0.00 | 67,500 | 0 | 201,500 | 134 K to 201.5 K (+50.37 %) |
| Jul 26 2013 | LBIO | Lion Biotechnologi ... | VOYTICKY DAVID J | Director | Grant | A | 0.00 | 13,353,215 | 0 | 13,353,215 | 0 to 13.4 M |
| Jul 26 2013 | LBIO | Lion Biotechnologi ... | MCPEAK MERRILL A/ | Interim President a ... | Grant | A | 0.00 | 13,353,215 | 0 | 34,643,215 | 21.3 M to 34.6 M (+62.72 %) |